Show simple item record

dc.contributor.authorAbarrategi, Ander 
dc.contributor.authorTornin, Juan
dc.contributor.authorMartinez-Cruzado, Lucia
dc.contributor.authorHamilton, Ashley
dc.contributor.authorMartinez-Campos, Enrique
dc.contributor.authorBaldini, Nicola
dc.contributor.authorRodriguez, Rene
dc.contributor.authorRodrigo, Juan P.
dc.contributor.authorGonzález, M. Victoria
dc.contributor.authorGarcia-Castro, Javier 
dc.date.accessioned2020-07-06T15:26:36Z
dc.date.available2020-07-06T15:26:36Z
dc.date.issued2016
dc.identifier.citationStem Cells Int . 2016;2016:3631764es_ES
dc.identifier.issn1687-966Xes_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/10669
dc.description.abstractOsteosarcoma (OS) is the most common type of primary solid tumor that develops in bone. Although standard chemotherapy has significantly improved long-term survival over the past few decades, the outcome for those patients with metastatic or recurrent OS remains dismally poor and, therefore, novel agents and treatment regimens are urgently required. A hypothesis to explain the resistance of OS to chemotherapy is the existence of drug resistant CSCs with progenitor properties that are responsible of tumor relapses and metastasis. These subpopulations of CSCs commonly emerge during tumor evolution from the cell-of-origin, which are the normal cells that acquire the first cancer-promoting mutations to initiate tumor formation. In OS, several cell types along the osteogenic lineage have been proposed as cell-of-origin. Both the cell-of-origin and their derived CSC subpopulations are highly influenced by environmental and epigenetic factors and, therefore, targeting the OS-CSC environment and niche is the rationale for many recently postulated therapies. Likewise, some strategies for targeting CSC-associated signaling pathways have already been tested in both preclinical and clinical settings. This review recapitulates current OS cell-of-origin models, the properties of the OS-CSC and its niche, and potential new therapies able to target OS-CSCs.es_ES
dc.description.sponsorshipThis work was supported by the Plan Nacional 2008–2011 (ISC III/FEDER (Miguel Servet Program CP11/00024) and RTICC (RD12/0036/0015)), the Plan Nacional 2013–2016 (MINECO/FEDER (SAF-2013-42946-R)), and the Plan de Ciencia Tecnología e Innovación del Principado de Asturias (GRUPIN14-003), to Rene Rodriguez, and the Plan Nacional 2008–2011 (ISC III/FEDER (PI11/00377) and RTICC (RD12/0036/0027)), to Javier Garcia-Castro.es_ES
dc.language.isoenges_ES
dc.publisherHindawi es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.titleOsteosarcoma: Cells-of-Origin, Cancer Stem Cells, and Targeted Therapies.es_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID27366153es_ES
dc.format.volume2016es_ES
dc.format.page3631764es_ES
dc.identifier.doi10.1155/2016/3631764es_ES
dc.contributor.funderUnión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF) 
dc.contributor.funderMinisterio de Economía y Competitividad (España) 
dc.contributor.funderGobierno del Principado de Asturias (España) 
dc.description.peerreviewedes_ES
dc.identifier.e-issn1687-9678es_ES
dc.relation.publisherversionhttps://doi.org/10.1155/2016/3631764es_ES
dc.identifier.journalStem cells internationales_ES
dc.repisalud.centroISCIII::Instituto de Investigación de Enfermedades Rarases_ES
dc.repisalud.institucionISCIIIes_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/ CP11/00024es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/RD12/0036/0015es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/SAF-2013-42946-Res_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/GRUPIN14-00es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/PI11/00377es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/RD12/0036/0027es_ES
dc.rights.accessRightsopen accesses_ES


Files in this item

Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This item is licensed under a: Atribución 4.0 Internacional